Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (tdap) vaccine from the advisory committee on immunization practices, 2010

Morbidity and Mortality Weekly Report

Volumn 60, Issue 1 RR, 2011, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78751635895     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. CDC. Final 2009 reports of nationally notifiable diseases. MMWR 2010;59;1025,1027-39.
2. CDC. National, state, and local area vaccination coverage among adolescents aged 13-17 years--United States, 2009. MMWR 2010;59;1018-23.
3. CDC. Tetanus and pertussis vaccination coverage among adults aged ≥18 years--United States, 1999 and 2008. MMWR 2010;59:1302-6.
4. CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR 2006;55(No. RR-17).
5. CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-3).
6. Halperin SA, Sweet L, Baxendale D, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J 2006;25:195-200.
7. Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009;5:315-21.
8. Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KP. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010;28:8001-7.
9. Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee. Day one. Bethesda, MD: Food and Drug Administration. Available at http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3300t1.pdfinfiggraphic filenameifig1//infiginfiggraphic filenameifig2//infig. Accessed January 10, 2011.
10. Sänger R, Behre U, Krause KH, et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr 2007;166:1229-36.
11. Langley JM, Predy G, Guasparini R, et al. An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 2007;25:1121-5.
12. Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccin 2008;4:203-9.
13. Scheifele DW, Halperin SA, Ochnio JJ, Ferguson AC, Skowronski DM. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 2005;24:1059-66.